MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why MGX Stock advanced +1.03% Today — RQD Quant Desk Flash
$0.83 +1.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.83
Metagenomi Therapeutics Inc. (MGX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $31.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.83 (+0.00%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY MGX SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (37% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (32% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 30.9 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.00-22% Next Q
49
Q2 (-2Q)Grade D$0.78+3.8% Next Q
46
Q3 (-1Q)Grade D$0.81+2.5% Next Q
44
CurrentGrade D-$0.83-7.2% Hist 90D α
41
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MGX Turnaround Squeeze
While MGX currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($0.87) forces dealer call-delta covering toward $2.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MGX Stock advanced +1.03% Today — RQD Quant Desk Flash
Metagenomi Therapeutics Inc. (MGX) advanced +1.03% to $0.83, trading at 4% of its 52-week range ($0.75 – $2.55). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($0.75 – $2.55) with RSI-14 at 30.9 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.83 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MGX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MGX)
- ✓Walkthrough of MGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -39.86%▼ DESCENDING CHANNEL
2026-10-30O $0.78H $0.83L $0.78C $0.83VOL 77.8K
RES: $1.09SUP: $0.73SMA50: $1.04SMA200: $1.29
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -51.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MGX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MGX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MGX)
Health Care Rank #621 of 1016
⚔️ ALGS vs MGX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MGX vs. ALGS, ESLA, GNTA, EVAX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Metagenomi Therapeutics Inc. (MGX) ranks #621 by composite RQD confidence (41/100, grade D-) and #801 by equity capitalization ($31.4M). Within this direct 5-issuer industry benchmark cohort, MGX leads on earnings valuation at N/A trailing P/E, while MGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with MGX at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MGX
ACTIVE
Metagenomi Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | +1.03% | $31.4M | Benchmark Subject |
| ALGS Aligos Therapeutics Inc. | E | 26/100 | — | — | -35.0% | -2.71% | $31.4M | /algs-vs-mgx → |
| ESLA Estrella Immunopharma Inc. | D- | 41/100 | — | — | -35.0% | -11.32% | $31.7M | /esla-vs-mgx → |
| GNTA Genenta Science S.p.A. | C | 62/100 | — | — | — | +2.48% | $29.9M | /gnta-vs-mgx → |
| EVAX Evaxion A/S | D+ | 58/100 | — | — | — | -0.96% | $27.8M | /evax-vs-mgx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001785279In its most recent audited fiscal period (FY2025, filed 2025-12-31), Metagenomi Therapeutics Inc. (MGX) reported GAAP revenue of $25.2M (-51.8% vs. FY2024 revenue of $52.3M , and -43.7% cumulative change since FY2023) , GAAP net income of -$87.9M, operating cash flow of -$88.9M, and free cash flow of -$89.5M (+20.3% YoY). On the balance sheet, MGX closed FY2025 with $221.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $25.2M | -$87.9M | -$88.9M | -$89.5M | $221.1M | — |
| FY2024 (FY) | 2024-12-31 | $52.3M | -$78.1M | -$109.1M | -$112.2M | $324.6M | — |
| FY2023 (FY) | 2023-12-31 | $44.8M | -$68.3M | -$91.4M | -$91.4M | — | — |
3. MGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Metagenomi Therapeutics Inc. (NASDAQ: MGX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.83 (+1.03% 1D, market cap $31.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MGX ranks #621 in composite RQD confidence.
How does MGX compare to ALGS and ESLA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALGS (Aligos Therapeutics Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, MGX leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MGX?
Per MGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785279), Metagenomi Therapeutics Inc. generated $25.2M in revenue (-51.8% YoY), -$87.9M in net income, and -$89.5M in free cash flow against $221.1M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MGX trading relative to its 50-day, 200-day, and 52-week technical levels?
MGX last traded at $0.83 (+1.03% on volume of 72,041 shares), positioning the stock -20.19% below its 50-day simple moving average ($1.04) and -35.66% below its 200-day simple moving average ($1.29). Across its 52-week range of $0.75 to $2.55, MGX sits at the 4.4% percentile with a 14-day RSI of 30.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.93).
MGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MGX stock moving today?
Why MGX Stock advanced +1.03% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.